Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Bipolar DisorderSubstance Use Disorder
Interventions
DRUG

Icariin

Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.

Trial Locations (1)

75390-8849

The University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT01979133 - Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders | Biotech Hunter | Biotech Hunter